Market revenue in 2023 | USD 1,977.0 million |
Market revenue in 2030 | USD 4,259.6 million |
Growth rate | 11.6% (CAGR from 2023 to 2030) |
Largest segment | Hba1c tests |
Fastest growing segment | HGB/HCT tests |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Complete blood count, HGB/HCT tests, Basic metabolic panel, BUN creatinine tests, Electrolytes testing, HbA1c tests, Comprehensive metabolic panel tests, Liver panel tests, Renal panel tests, Lipid panel tests |
Key market players worldwide | Quest Diagnostics Inc, Abbott Laboratories, Labcorp Holdings Inc, ARUP Laboratories, OPKO Health Inc, Clinical Reference Laboratory, Sonic Healthcare Ltd, Cinven, Unilabs |
Hba1c tests was the largest segment with a revenue share of 11.88% in 2023. Horizon Databook has segmented the Australia clinical laboratory tests market based on complete blood count, hgb/hct tests, basic metabolic panel, bun creatinine tests, electrolytes testing, hba1c tests, comprehensive metabolic panel tests, liver panel tests, renal panel tests, lipid panel tests covering the revenue growth of each sub-segment from 2018 to 2030.
The prevalence of diseases, such as diabetes and cardiovascular disorders, is growing in Australia. For instance, according to Baker Heart and Diabetes Institute, over 330,000 individuals in Australia are suffering from atrial fibrillation, and its prevalence can largely be attributed to diabetes. The prevalence of cancer is growing in the country.
Around 150,000 cancer cases were estimated to be diagnosed in 2020, and this number is expected to rise to 239,770 by 2030. Furthermore, in 2022, over 1.29 million people in the country had diabetes. In addition, one in four people living with diabetes remains undiagnosed.
Each year, over 500 million tests are delivered, which play a critical role in patient care and clinical decision-making. Routine tests account for 80% of the tests conducted in the country. In addition, the annual increase in patient burden on clinical laboratories is 5% to 10%. This is expected to increase the competition in the Australia market.
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account